TC BioPharm, a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced a corporate restructuring plan to reduce costs and prioritize its pending lead U.S. clinical programs.   In connection with the restructuring, the company is reducing its workforce up to 30%, with the majority of the reduction expected to be completed during the first half 2023.  The remaining team will support both current and future clinical trials and combina...